Sun Pharma to acquire Ranbaxy in $3.2 bn deal
Sun Pharmaceutical has decided to acquire the troubled pharma company Ranbaxy Laboratories in a $3.2 billion all-share deal. Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a Sun Pharmaceutical share for each Ranbaxy share they own.
Dr Reddys Laboratories plans to invest US$400mn
Dr Reddys Laboratories is planning to invest USD 400 mn on R&D over 3-4 years in biologics and proprietary products. The company had 21 active products in the proprietary products pipeline, of which six were in clinical development stage as on March 31, 2013.
SBI to sell NPAs of Rs. 40bn to ARCs
State Bank of India is selling off its non-performing assets of around Rs 40 billion for the financial year 2013-14 to asset reconstruction companies.
JSW Crude Steel production grew 43% in FY2013-14
Sun Pharmaceutical has decided to acquire the troubled pharma company Ranbaxy Laboratories in a $3.2 billion all-share deal. Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a Sun Pharmaceutical share for each Ranbaxy share they own.
Dr Reddys Laboratories plans to invest US$400mn
Dr Reddys Laboratories is planning to invest USD 400 mn on R&D over 3-4 years in biologics and proprietary products. The company had 21 active products in the proprietary products pipeline, of which six were in clinical development stage as on March 31, 2013.
SBI to sell NPAs of Rs. 40bn to ARCs
State Bank of India is selling off its non-performing assets of around Rs 40 billion for the financial year 2013-14 to asset reconstruction companies.
JSW Crude Steel production grew 43% in FY2013-14
JSW Steel Ltd. guided Crude Steel production target of 12 Million
tonnes for FY 2013-14. Inspite of tough business environment of slow growth,
inadequate availability& poor quality of Iron ore and shortage of Natural
gas, the Company exceeded the guidance for Crude steel production by 0.17
million tonnes.
0 comments:
Post a Comment